Our research benefits from an external network of industry alliances focused on exploring new approaches to biomedical research and early-stage drug discovery for patient benefit. Some of our most powerful alliances are:
UCL successfully coordinated a £16 million bid to work with the Medical Research Council, GlaxoSmithKline (GSK) and four other leading universities to improve scientists’ understanding of inflammatory and fibrotic diseases that present a serious burden to patients.
The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network brings together teams of researchers from UCL, the Universities of Glasgow, Cambridge, Newcastle and Imperial College London, with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases.
The bid was drafted and led by BRC supported Professor Rachel Chambers, Vice-Dean (Enterprise) for the UCL Faculty of Medical Sciences and Director of the Centre for Inflammation and Tissue Repair.
EMINENT has developed into a full strategic relationship between GSK Respiratory Therapeutic Area and UCLH/UCL with the recent signing (April 2017) of the respiratory Hub.
UCL and Takeda Pharmaceutical Company Limited entered into a research collaboration to identify and validate novel target genes for the treatment of neurodegenerative disease.
This collaboration focused on mechanistic approaches for the identification of genes or signalling pathways that modify neurodegenerative disease processes affecting neuronal health such as neuron disease, Huntington’s disease and Parkinson’s disease.
The collaboration includes support from our BRC.
UCL and Japanese pharmaceutical company Eisai entered into an agreement to establish a major drug discovery and development collaboration.
As a result of the collaboration, UCL and Eisai formed the Therapeutic Innovation Group, which consisted of experienced scientists from UCL and Eisai with the principal function of facilitating and coordinating the discovery and assessment of emerging therapeutic targets involved in neurological diseases.
UCL and pharmaceutical company Cell Medica have collaborated to develop modified T cell receptor products for the treatment of cancer.
UCL has provided Cell Medica with an exclusive license to its novel T cell receptor (TCR) technology to generate leading-edge modified TCR products.
T cell receptors are molecules found on the surface of T cells which recognise antigens expressed by cancer cells. TCR technology exploits the ability of TCRs to target both intracellular and cell surface antigens, providing an important mechanism to engineer immune cells to target tumours. The UCL TCR technology has the potential to produce strong expression of TCRs by the engineered T cells which is expected to improve their efficacy in fighting tumours.
The collaboration builds on the research of BRC Infection, Immunity and Inflammation Programme Director Professor Emma Morris and Professor Hans Stauss, global leaders in developing modified TCRs for cancer treatments.